National Cohort of Children Born to HIV-positive Mothers
Launched by ANRS, EMERGING INFECTIOUS DISEASES · Oct 4, 2017
Trial Information
Current as of May 16, 2025
Unknown status
Keywords
ClinConnect Summary
The goal of the CO11 national cohort is to provide with CO1 a wider surveillance system to monitor changes in the rate of mother to child transmission and preventive practices in France and especially to identify the occurrence of toxicity in children exposed perinatally to antiretroviral drugs.
The CO11 EPF enrolle HIV infected women who delivery in maternity generally smaller than CO1 maternity (15 sites in Paris area, 35 in mainland France and 4 in the DOM).
Maternal clinical, biological and therapeutic data before and during pregnancy were collected at delivery, with simplified questi...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • pregnant women \>= 18 years
- • infected with HIV1 and/or HIV2
- Exclusion Criteria:
- • guardianship or judicial or administrative detention
About Anrs, Emerging Infectious Diseases
ANRS, the French National Agency for Research on AIDS and Viral Hepatitis, is a prominent research organization dedicated to advancing scientific knowledge and public health responses to emerging infectious diseases. With a focus on enhancing understanding, prevention, and treatment of viral infections, ANRS conducts and supports innovative clinical trials that address urgent health challenges. By fostering collaboration among researchers, healthcare professionals, and institutions, ANRS aims to translate research findings into effective strategies that improve patient outcomes and inform public health policies. Their commitment to addressing the dynamic landscape of infectious diseases positions them as a leader in global health research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nancy, , France
Saint Etienne, , France
Angers, , France
Rouen, , France
Rennes, , France
Lorient, , France
Tours, , France
Bayonne, , France
Pontoise, , France
Orléans, , France
Vannes, , France
Bordeaux, , France
Nîmes, , France
Amiens, , France
Melun, , France
Angers, , France
Annecy, , France
Aulnay, , France
Bastia, , France
Besançon, , France
Brest, , France
Béziers, , France
Caen, , France
Chalon Sur Saone, , France
Creil, , France
Dijon, , France
Evreux, , France
Fontainebleau, , France
La Roche Sur Yon, , France
Lagny Sur Marne, , France
Le Chesnay, , France
Limoges, , France
Longjumeau, , France
Mantes La Jolie, , France
Maux, , France
Montfermeil, , France
Orsay, , France
Paris, , France
Perpignan, , France
Poissy, , France
Provins, , France
Quimper, , France
Reims, , France
Saint Brieuc, , France
Saint Julien, , France
Saint Nazaire, , France
Saint Martin, , France
Toulon, , France
Vernon, , France
Villeneuve Saint Georges, , France
Cayenne, , French Guiana
Pointe à Pitre, , Guadeloupe
Fort De France, , Martinique
Patients applied
Trial Officials
Josiane WARSZAWSKI
Principal Investigator
CESP INSERM U1018
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials